lifestyle.digitaladblog.com

Author: OKYO Pharma LTD

OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

February 12, 2026
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

January 30, 2026
OKYO Pharma Announces Successful Type C Meeting with the FDA

January 28, 2026
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain

January 23, 2026